Prof. Alwin Krämer, M.D.

Prof. Alwin Krämer, M.D.

Prof. Alwin Krämer, M.D.


Head of Division


Molecular Hematology/Oncology


+49 6221 42 1440


+49 6221 42 1444


INF 581/TP 4




From 2006: Division head at DKFZ
2005: Full Professor at the Faculty of Medicine, University of Heidelberg
2002-2005: Heisenberg Fellow at the Danish Cancer Society, Kopenhagen, Denmark
2002: Board-certified subspecialist for Hematology/Oncology
2000-2002: Assistant Professor at the Dept. of Internal Medicine, University of Heidelberg
1999: Board-certified physician (Internal Medicine)
1995-1996: Postdoctoral fellow McArdle Laboratory for Cancer Research, Madison, WI, USA
1992-2000: Residency at the Dept. of Internal Medicine, University of Heidelberg
1988-1992: Doctoral thesis (M.D.) at the University of Mainz
1985-1992: Study of medicine, University of Mainz, Germany and Bern, Switzerland

Awards and Fellowships

Scientific Award 2010, Working Group Medical Oncology (AIO) of the German Cancer Society
Vincenz-Czerny-Award, German Hematology/Oncology Association (DGHO)
Heisenberg fellowship, German Research Foundation (DFG)
Krebshilfe-Scholarship (German Cancer Aid)

Selected Publications

Castiel A, Danieli MM, David A, Moshkovitz S, Aplan PD, Kirsch IR, Brandeis M, Krämer A, Izraeli S: The STIL protein regulates centrosome integrity and mitosis through suppression of CHFR. Journal of Cell Science (accepted for publication), 2011.

Dietrich S, Hegenbart U, Andrulis M, Schmitt T, Bellos F, Martens U, Meissner J, Krämer A, Ho AD, Dreger P: Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: Results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biology of Blood and Marrow Transplantation (accepted for publication), 2011.

Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, Plinkert PK, Krämer A, Gertsch J, Efferth T: Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochemical Pharmacology (accepted for publication), 2011.

Löffler H*, Fechter A*, Matuszewska M, Saffrich R, Mistrik M, Marhold J, Hornung C, Westermann F, Bartek J, Krämer A: Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification and Genome Maintenance. Cancer Research (accepted for publication), 2011. *These authors contributed equally to this work.

Shahmoradgoli M, Mannherz O, Engel F, Heck S, Krämer A, Seiffert M, Pscherer A, Lichter P: Anti-apoptotic function of Charged Multivesicular Body Protein 5 (CHMP5), a potentially relevant gene in acute myeloid leukemia. International Journal of Cancer, Aug 23 (epub ahead of print), 2010.

Koledova Z, Kafkova LR, Krämer A*, Divoky V*: DNA Damage-induced degradation of Cdc25A does not inhibit Cdk2 activity in mouse embryonic stem cells. Stem Cells 28: 450-461, 2010. *shared corresponding authorship.

Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 2010.

Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD, Salisbury JL, Boutros M, Krämer A: Proteins required for centrosome clustering in cancer cells. Science Translational Medicine 2010.

Heilig CE*, Löffler H*, Mahlknecht U, Janssen JWG, Ho AD, Jauch A, Krämer A: Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. Journal of Cellular and Molecular Medicine 14: 895-902, 2010. *These authors contributed equally to this work.

Sellner L, Capper D, Meyer J, Langhans C-D, Hartog C-M, Pfeifer H, Serve H, Ho AD, Okun JG*, Krämer A*, von Deimling A*: Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. European Journal Haematology 2010. *shared corresponding authorship.

Koledova Z, Krämer A, Kafkova LR, Divoky V: Cell cycle regulation in embryonic stem cells: centrosomal decisions on self-renewal. Stem Cells and Development 2010

Krämer A: PML promotes senescence via JAK/STAT signaling. Cell Cycle 9, 2010

Rønnest MH, Rebacz B, Markworth L, Terp AH, Krämer A, Larsen TO, Clausen MH: Synthesis and structure-activity relationship of griseofulvin analogues as inhibitors of centrosomal clustering in cancer cells. Journal of Medicinal Chemistry 2009.

Tibelius A, Marhold J, Zentgraf H, Heilig CE, Neitzel H, Ducommun B, Rauch A, Ho AD, Bartek J, Krämer A: Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. Journal of Cell Biology 2009.

Neben K, Gattenlöhner S, Krämer A: Molekulare Pathogenese und Biologie des CUP-Syndroms. Der Pathologe 30: 117-124, 2009.

Hose D, Moreaux J, Meißner T, Seckinger A, Lewis J, Benesch V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr., Barlogie B, Neben K, Krämer A, Reme T, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H: Inhibition of aurora kinases as option for risk adapted tailored treatment in multiple myeloma. Blood 113: 4331-4340, 2009.

Witzens-Harig M, Reiz M, Heiß C, Benner A, Hensel M, Neben K, Dreger P, Krämer A, Ho AD: Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B-cell Non-Hodgkins-Lymphoma: Results of a prospective randomized controlled trial. Annals of Hematology 88: 51-57, 2009.

Neben K, Hübner G, Folprecht G, Jäger D, Krämer A: Metastasen ohne Primärtumor. Fortschritte in Diagnostik und Therapie des CUP-Syndroms. Deutsches Ärzteblatt 43: 733-740, 2008.

Krämer A: JAK2-V617F and BCR-ABL – double jeopardy? Leukemia Research 32: 1489-1490, 2008.

Krämer A, Raab MS, Rebacz B: Induction of spindle multipolarity by centrosomal cluster inhibition. Cellular Oncology 30: 505-506, 2008.

Neben K, Gattenlöhner S, Krämer A: Molekulare Pathogenese und Biologie des CUP-Syndroms. Der Onkologe 14: 860-869, 2008.

Krämer A, Hübner G, Schneeweiss A, Folprecht G, Neben K: Carcinoma of unknown primary – a orphan disease? Breast Care 3: 164-170, 2008.

Fabarius A, Giehl M, Rebacz B, Krämer A, Frank O, Haferlach C, Duesberg P, Hehlmann R, Seifarth W, Hochhaus A: Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93: 1145-1154, 2008.

Löffler H, Bochtler T, Fritz B, Tews B, Ho AD, Lukas J, Bartek J, Krämer A. DNA damage-induced accumulation of centrosomal Chk1 contribuites to its checkpoint function. Cell Cycle. Cell Cycle. 2007 Oct 15;6(20):2541-8.

Rebacz B, Larsen TO, Clausen MH, Rønnest MH, Löffler H, Ho AD, Krämer A. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res. 2007 Jul 1;67(13):6342-50.

Hensel M, Zoz M, Giesecke C, Benner A, Neben K, Jauch A, Stilgenbauer S, Ho AD, Krämer A. High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. Int J Cancer. 2007 Sep 1;121(5):978-83.

Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007 Jul;8(7):658-60.

Neben K, Ott G, Schweizer S, Kalla J, Tews B, Katzenberger T, Hahn M, Rosenwald A, Ho AD, Müller-Hermelink HK, Lichter P, Krämer A. Expression of centrosome-associated gene products is linked to tetraploidization in mantle cell lymphoma. Int J Cancer. 2007 Apr 15;120(8):1669-77.

Löffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Krämer A. Chk1-Dependent Regulation of Cdc25B Functions to Coordinate Mitotic Events. Cell Cycle. 2006 Nov 1;5(21):2543-7.

Löffler H, Lukas J, Bartek J, Krämer A. Structure meets function - Centrosomes, genome maintenance and the DNA damage response. Exp Cell Res. 2006 Aug 15;312(14):2633-40.

Krämer A, Neben K, Ho AD. Centrosome aberrations in hematological malignancies. Cell Biol Int. 2005 May;29(5):375-83. Review.

Krämer A. Centrosome aberrations - hen or egg in cancer initiation and progression? Leukemia. 2005 Jul;19(7):1142-4. Review

Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland J, Lukas C, Ørntoft T, Lukas J, Bartek J: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005.

Leo E, Scheuer L, Kerowgan M, Schmitt C, Leo A, Baumbach T, Parwaresch R, Krämer A, Ho AD: Severe thrombocytopenia associated with a combination of rituximab, fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. European Journal of Hematology 73: 251-257, 2004.

Krämer A, Lukas J, Bartek J. Checking out the centrosome. Cell Cycle. 2004 Nov;3(11):1390-3. Epub 2004 Nov 22.

Krämer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA, Bartek J, Lukas J. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol. 2004 Sep;6(9):884-91.

Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, Giesecke C, Krause U, Ho AD, Krämer A, Lichter P. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene. 2004 Mar 25;23(13):2379-84.

Seggewiss R, Ho AD, Krämer A. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia. Ann Hematol. 2004 May;83(5):316-8.

Krämer A, Schweizer S, Neben K, Giesecke C, Kalla J, Katzenberger T, Benner A, Muller-Hermelink HK, Ho AD, Ott G. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. Leukemia. 2003 Nov;17(11):2207-13.

Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD, Bastert G, Krämer A. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer. 2003 Nov 10;107(3):346-52.

Krämer A, Fruehauf S, Ho AD, Hager HD, Bartram CR, Hochhaus A. Novel constitutional t(2;12)(q21;q22) in a patient with t(9;22)-negative chronic myelocytic leukemia. Cancer Genet Cytogenet. 2003 Apr 15;142(2):162-4. No abstract available.

Neben K, Giesecke C, Schweizer S, Ho AD, Krämer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood. 2003 Jan 1;101(1):289-91. Epub 2002 Jun 28.

Neben K, Moehler T, Benner A, Krämer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002 Nov;8(11):3377-82.

Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H, Hehlmann R. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia. 2002 Sep;16(9):1844-51.

Neben K, Mytilineos J, Moehler TM, Preiss A, Krämer A, Ho AD, Opelz G, Goldschmidt H. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002 Sep 15;100(6):2263-5.

Krämer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia. 2002 May;16(5):767-75. Review.

Neben K, Moehler T, Krämer A, Benner A, Egerer G, Ho AD, Goldschmidt H. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol. 2001 Dec;115(3):605-8.

Krämer A, Löffler H, Bergmann J, Hochhaus A, Hehlmann R. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia. 2001 Jan;15(1):62-8.

Krämer A, Ho AD. Centrosome aberrations and cancer. Onkologie. 2001 Dec;24(6):538-44. Review.

Neben K, Moehler T, Egerer G, Krämer A, Hillengass J, Benner A, Ho AD, Goldschmidt H. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res. 2001 Sep;7(9):2675-81.

Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Krämer A, Yerganian G, Hehlmann R. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 2000 Jun;119(2):83-93.

Schultheis B, Krämer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 1999 Dec;13(12):2099-103.

Krämer A, Horner S, Willer A, Fruehauf S, Hochhaus A, Hallek M, Hehlmann R. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2087-92.

Fruehauf S, Veldwijk MR, Krämer A, Haas R, Zeller WJ. Delineation of cell cycle state and correlation to adhesion molecule expression of human CD34+ cells from steady-state bone marrow and peripheral blood mobilized following G-CSF-supported chemotherapy. Stem Cells. 1998;16(4):271-9.

Krämer A, Hochhaus A, Saussele S, Reichert A, Willer A, Hehlmann R. Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation. Leukemia. 1998 Jun;12(6):893-8.

Li R, Yerganian G, Duesberg P, Krämer A, Willer A, Rausch C, Hehlmann R. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14506-11.

Krämer A, Carstens CP, Wasserman WW, Fahl WE. CBP/cycA, a CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription, consists of NF-Y and a novel Mr 115,000 subunit. Cancer Res. 1997 Nov 15;57(22):5117-21.

Carstens CP, Krämer A, Fahl WE. Adhesion-dependent control of cyclin E/cdk2 activity and cell cycle progression in normal cells but not in Ha-ras transformed NRK cells. Exp Cell Res. 1996 Nov 25;229(1):86-92.

Krämer A, Carstens CP, Fahl WE. A novel CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription at the G1/S boundary is sequestered by a retinoblastoma-like protein in G0. J Biol Chem. 1996 Mar 22;271(12):6579-82.

to top